Nayef M Kazzaz1, W Joseph McCune, Jason S Knight. 1. Division of Rheumatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Abstract
PURPOSE OF REVIEW: Catastrophic antiphospholipid syndrome (CAPS) is a severe manifestation of antiphospholipid syndrome (APS). Although affecting only 1% of patients with APS, the condition is frequently fatal if not recognized and treated early. Here, we will review the current approach to diagnosis and treatment of CAPS. RECENT FINDINGS: Data from the international 'CAPS registry', spearheaded by the European Forum on Antiphospholipid Antibodies, have improved our understanding of at-risk patients, typical clinical features, and precipitating diagnoses. Current guidelines also continue to support the role of anticoagulants and glucocorticoids as foundation therapy in all patients. Finally, new basic science and case series suggest that novel therapies, such as rituximab and eculizumab, warrant further study. SUMMARY: Attention to associated diagnoses, such as infection and systemic lupus erythematosus (SLE), is critical at the time of diagnosis. All patients should be treated with anticoagulants, corticosteroids, and possibly plasma exchange. In patients with SLE, cyclophosphamide should be considered. In refractory or relapsing cases, new therapies, such as rituximab and possibly eculizumab, may be options, but need further study.
PURPOSE OF REVIEW: Catastrophic antiphospholipid syndrome (CAPS) is a severe manifestation of antiphospholipid syndrome (APS). Although affecting only 1% of patients with APS, the condition is frequently fatal if not recognized and treated early. Here, we will review the current approach to diagnosis and treatment of CAPS. RECENT FINDINGS: Data from the international 'CAPS registry', spearheaded by the European Forum on Antiphospholipid Antibodies, have improved our understanding of at-risk patients, typical clinical features, and precipitating diagnoses. Current guidelines also continue to support the role of anticoagulants and glucocorticoids as foundation therapy in all patients. Finally, new basic science and case series suggest that novel therapies, such as rituximab and eculizumab, warrant further study. SUMMARY: Attention to associated diagnoses, such as infection and systemic lupus erythematosus (SLE), is critical at the time of diagnosis. All patients should be treated with anticoagulants, corticosteroids, and possibly plasma exchange. In patients with SLE, cyclophosphamide should be considered. In refractory or relapsing cases, new therapies, such as rituximab and possibly eculizumab, may be options, but need further study.
Authors: José A Gómez-Puerta; Ricard Cervera; Gerard Espinosa; Ronald A Asherson; Mario García-Carrasco; Izaias P da Costa; Danieli C O Andrade; Eduardo F Borba; Alexander Makatsaria; Silvia Bucciarelli; Manuel Ramos-Casals; Josep Font Journal: Ann Rheum Dis Date: 2007-01-12 Impact factor: 19.103
Authors: Mirhelen M Abreu; Adriana Danowski; Denis G Wahl; Mary-Carmen Amigo; Maria Tektonidou; Marcelo S Pacheco; Norma Fleming; Vinicius Domingues; Savino Sciascia; Julia O Lyra; Michelle Petri; Munther Khamashta; Roger A Levy Journal: Autoimmun Rev Date: 2015-01-29 Impact factor: 9.754
Authors: Srilakshmi Yalavarthi; Travis J Gould; Ashish N Rao; Levi F Mazza; Alexandra E Morris; Carlos Núñez-Álvarez; Diego Hernández-Ramírez; Paula L Bockenstedt; Patricia C Liaw; Antonio R Cabral; Jason S Knight Journal: Arthritis Rheumatol Date: 2015-11 Impact factor: 10.995
Authors: W Miesbach; R A Asherson; R Cervera; Y Shoenfeld; J Gomez Puerta; S Bucciarelli; G Espinoza; J Font Journal: Autoimmun Rev Date: 2006-07-21 Impact factor: 9.754
Authors: Andreas Kronbichler; Renate Frank; Michael Kirschfink; Ágnes Szilágyi; Dorottya Csuka; Zoltán Prohászka; Peter Schratzberger; Karl Lhotta; Gert Mayer Journal: Medicine (Baltimore) Date: 2014-11 Impact factor: 1.889
Authors: Nayef M Kazzaz; Allecia M Wilson; Ruba Kado; Geoffrey D Barnes; Jason S Knight Journal: Arthritis Care Res (Hoboken) Date: 2017-08 Impact factor: 4.794